NsGene A/S
19Patents
13Active
19Granted
45Portfolio score
Filing activity: Jul 2, 1999 → Aug 22, 2014 · 7 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6593133B1 | Neurotrophic factors | Human Necessities | 20 | Expired |
| US6734284B1 | Neublastin neurotrophic factors | Human Necessities | 18 | Expired |
| US7276580B2 | Neurotrophic factors | Human Necessities | 12 | Expired |
| US7655463B2 | Methods of activating RET receptor tyrosine kinase using neurotrophic factors | Human Necessities | 11 | Active |
| US7358228B2 | Methods of treating pain using neurotrophic factors | Human Necessities | 11 | Active |
| US7601518B2 | Secretion of neublastin | Chemistry; Metallurgy | 10 | Expired |
| US7303912B2 | Cultures of GFAP nestin cells that differentiate to neurons | Chemistry; Metallurgy | 6 | Expired |
| US8404642B2 | Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain | Human Necessities | 6 | Active |
| US7651853B2 | Cultures of GFAP+ nestin+ cells that differentiate to neurons | Chemistry; Metallurgy | 4 | Active |
| US6555674B2 | JeT promoter | Chemistry; Metallurgy | 3 | Expired |
| US9068015B2 | Therapeutic use of a growth factor, METRNL | Human Necessities | 2 | Active |
| US8741340B2 | Cell lines and their use in encapsulated cell biodelivery | Chemistry; Metallurgy | 2 | Active |
| US8217146B2 | Neurotrophic factors and methods of use thereof | Human Necessities | 2 | Active |
| US9121037B2 | Cell lines and their use in encapsulated cell biodelivery | Chemistry; Metallurgy | 2 | Active |
| US8815810B2 | Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain | Human Necessities | 1 | Active |
| US9474786B2 | Treatment of allodynia | Human Necessities | 0 | Active |
| US8088567B2 | Human immortalised neural precursor cell line | Chemistry; Metallurgy | 0 | Active |
| US9364427B2 | Implantable therapy system for treating a living being with an active factor | Human Necessities | 0 | Active |
| US9314502B2 | Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.